Piton Therapeutics

Piton Therapeutics is creating first-in-class therapeutics for chronic conditions currently with limited treatment options. Several diseases are now being linked to disruptions of the human gut microbiome. Using their proprietary platform, Piton is discerning the gut microbiome’s role in the cause and progression of disease. The aim is to create small molecule drugs that can target pathogenic pathways in the gut lumen - Piton is using AI capabilities to enhance this search. Currently, Piton is developing treatments for Ulcerative Colitis, Autism Spectrum Disorder and Parkinson’s disease, with human trials for Ulcerative Colitis anticipated in 2025.

Jobs: